Investor focus: MMC Ventures 

How are rapid advances in emerging technologies reshaping investment priorities? Charlotte Barttelot, Partner at MMC Ventures, shares how research-led insights inform the firm’s investment strategy, including its focus on early-stage companies across Europe that have the potential to reshape entire sectors. Charlotte also reflects on where artificial intelligence (AI) could have the biggest benefit for healthcare and how the system can support the adoption of innovation at scale.

Interested in learning more about investment for healthtech innovation? Sign up to the HIN Investment Update.

Rapid advances in emerging technologies and secure healthcare data infrastructure are creating new opportunities to scale digital health products. MMC Ventures works closely with startups to understand the technology and system dynamics that are shaping industries and the wider economy. Charlotte Barttelot, for example, specialises in data-driven health and enterprise software. As a partner at this research-led firm, she looks for businesses that have the potential to make the biggest impact on society.

In this Investor Focus, Charlotte discusses the opportunities emerging from artificial intelligence (AI), what MMC Ventures looks for in founders, and how healthcare organisations can better support innovation adoption.

Looking beyond technology

MMC Ventures is a London based venture capital fund that invests in and supports early-stage founders. The firm are particularly interested in AI and data companies, providing pre-seed, seed or Series A funding to companies that have the potential to reshape entire sectors.

“We’re looking for technologies that transform industries,” says Charlotte. “We spend a lot of time researching what good looks like and then combine that with where we see the biggest problems in the healthcare industry.”

This approach has led MMC Ventures to back companies across healthcare delivery, pharmaceuticals and deep science. This breadth is reflected in investments ranging from healthcare companies such as Synteny.ai, Sano Genetics and Wawa Fertility, through to deep technology businesses including Cambridge Touch Technologies.

Rather than being driven by specific trends in emerging technology, the team look for startups that have a sustainable protectory for success. This means identifying companies that understand their customers, solve genuine problems and have the capabilities to implement at speed.   

“In terms of the latest platform shift with AI, the technology moat stands for less,” she explains. “We’re looking for teams that deeply understand the problems of their customers.”

As a result, MMC Ventures’ portfolio spans start-ups based across Europe, from C the Signs, which uses AI for early cancer detection, to DigitalHealth.London alumni PocDoc.

Identifying opportunities through research  

One area that MMC Ventures is deeply invested in is data-driven health. They recently conducted extensive research into where generative AI could have the greatest impact on healthcare administration and operations. Staff shortages and burnout was identified as key challenges, highlighting the potential for emerging technologies to improve non-clinical workflows and reduce administrative burden.

Charlotte points to portfolio company Frontier Health as a company that is addressing this challenge. MMC Ventures’ interest was not only driven by its use of artificial intelligence to automate workflows, but also by its ability to solve a clearly defined operational challenge and demonstrate measurable return on investment (ROI). “[We look for companies that are] able to really solve a pain point, as opposed to just being a new technology for a problem that may or may not exist,” she explains.

Beyond healthcare delivery, Charlotte also sees significant opportunities across pharmaceutical research and development. MMC Ventures is particularly interested in technologies that help organisations work more efficiently. Opportunities include improving how clinical trials are run, streamlining collaboration between pharmaceutical companies and healthcare professionals, and reducing the time and cost required to bring new treatments to market.

Balancing emerging technology and sustainable growth  

Looking ahead, Charlotte is optimistic about the potential of emerging technologies across healthcare and life sciences. From improving operational efficiency to accelerating research and development, she sees significant opportunities for companies and systems willing to explore new approaches.

When evaluating early-stage companies, MMC Ventures looks for ambition alongside the ability to attract top talent, navigate setbacks and maintain momentum through uncertainty.

Resilience is a really important thing for a founder. You get told ‘no’ a lot.

This approach highlights the importance of building sustainable businesses, not just innovative technologies. While the technologies themselves will continue to evolve, Charlotte believes success will ultimately depend on how effectively organisations adopt them and integrate them into everyday practice. She reflects: “There’s an amazing opportunity right now for healthcare decision makers to embrace what’s in front of them.”

Proprietary data, strong market positioning and customer relationships are all critical enablers of adaption and scale. By embedding these foundations from the outset, startups are better positioned to navigate challenges and achieve long-term growth.

Subscribe to the HIN Investment Update for key investment news, exclusive insights from the HIN’s investor network, and the latest opportunities and events. Ideal for growing healthtech companies, as well as funders and investors shaping the health innovation ecosystem.